Corrections and scope clarifications

When we correct a material statement or clarify its limits, we record the change here so you can see what changed and why.

Rusfertide approval and setmelanotide scope

Corrected the outdated pending-review description for rusfertide after the FDA Mimrylo decision. Added the acquired hypothalamic obesity indication and distinct age boundary to setmelanotide. Both pages link to the authoritative decision or label.

FDA development diagrams

Removed the generic seven-stage ladder from fact sheets. It could suggest completed milestones or a drug-development path where the cited records did not establish one. NAD+ now shows source scope without the ladder.

Semaglutide formulation and indication scope

Added separate Wegovy injection and tablet records. The injection-only MASH indication and pediatric scope must not be transferred to tablets. See the prescribing information, section 1 and the human-evidence table.

Trial status and results availability

Separated phase, recruitment, registry results and publication. The checked TRIUMPH-1 record is completed without posted registry results; that is not a statement that no results exist elsewhere. Registry record.

Source checks for these changes: 2026-09-18. Send further corrections privately through contact; personal treatment anecdotes are not published as evidence.